Rocket Lab's Two-Lane Race: Cash-Flow Machine vs. the Neutron Clock

Rocket Lab's Electron business thrives with record revenue and GHOST launch platform, but Neutron delays and stock decline create investor tension.

The most telling detail in Rocket Lab's recent news cycle wasn't the headline-grabbing Iridium takeover progress or the record revenue figures. It was a modest announcement tucked between bigger items: the GHOST portable launch platform. Designed to make Electron and HASTE missions more flexible and location-independent — with an eye toward multiple launch campaigns and security-related missions — GHOST signals that management is determined to keep evolving its bread-and-butter business regardless of how the big Neutron bet plays out.

That distinction between the established operation and the future gamble has become the central tension for investors. The operational side keeps delivering. Over the weekend of August 20–21, the company flew its 93rd Electron mission from Launch Complex 1 in New Zealand — the 14th launch of 2026 — carrying a QPS-SAR payload for Japanese Earth-observation customer iQPS. It marked the ninth such mission for iQPS, with nine more under contract, and Rocket Lab touted a 100% success rate for the flight.

Just days earlier, on August 16, the company confirmed that eight of 17 satellite platforms from its $143 million contract with MDA Space — tied to Globalstar's direct-to-device services — had reached orbit. The order book is filling in other places too: a dedicated Neutron customer launch for Kepler Communications is secured for no earlier than 2028, departing from Launch Complex 3 in Wallops Island.

The revenue trajectory reinforces the picture of a company in its operational prime. Second-quarter 2026 sales climbed 62% year-over-year to $234 million, and management has guided toward another record quarter in Q3. The antitrust review of the proposed Iridium Communications acquisition was also wrapped up in mid-August, clearing one more hurdle on that front.

Yet the share price tells a different story. The stock traded at €59.50 in the primary reporting window — roughly 16% below its level seven days earlier — while a second source put the Friday quote at €62.40, down about 12% week-over-week and 13% beneath the 50-day moving average of €71.40. Either way, the equity sits roughly 53–56% off its 52-week high of €133.80, set in May. Annualized volatility runs near 79%.

The culprit is Neutron. On August 10, Rocket Lab reaffirmed that first-stage production remains on track for delivery to the launch pad in Q4 2026 — but the exact timing of the debut flight depends on subsequent qualification tests. Reuters reported that the company has dialed back its confidence in a first launch this year, and Bloomberg has flagged 2027 as a realistic slip scenario. The stock's after-hours reaction to that news was negative, and the uncertainty has since colored the entire tape.

The market's math is straightforward: Neutron is the growth engine that opens segments currently dominated by SpaceX and a handful of others. Every delay chips away at the credibility of the timeline, even as the Electron business posts record numbers. The risk is that investors begin to read a pattern rather than an isolated setback — and the drawdown from the May high suggests expectations for this stock are unusually sensitive to scheduling news.

There's a bull case buried in the same facts. If the first stage ships on schedule in Q4 and qualification tests proceed without major hiccups, a debut late this year or early 2027 remains plausible. Kepler's commitment shows customers are willing to plan around the program despite the delays. GHOST, meanwhile, could extend Electron's commercial runway and generate steady cash flow while Neutron development continues. The Iridium deal, if consummated, would broaden the portfolio further.

The bear case leans on the combination of technical complexity and time pressure. Rocket Lab itself hasn't ruled out a slip beyond 2026 — the language remains conditional, but management is clearly taking the possibility seriously. A further delay would likely be treated as a pattern, not an outlier. And the Iridium transaction, should it close, would tie up capital and management bandwidth that Neutron also needs.

For now, the stock is caught between two forces: an operating business firing on all cylinders and a flagship project whose timetable the market no longer fully trusts. The next concrete checkpoint is the Q3 revenue report, paired with updates on first-stage manufacturing. Until then, expect the shares to oscillate with every scrap of Neutron news — and the patience of even committed holders to be tested.